Allakos (ALLK) 2022 Earnings Call Presentation

Clinical Study Results - KRYPTOS (EoE) - In the KRYPTOS Phase 2/3 EoE study, 88% of patients in the high dose lirentelimab group (n=91) achieved histologic response (≤6 eos/hpf at Week 24) compared to 11% in the placebo group (n=92)[21] - Complete histologic remission (≤1 Eos/hpf at Week 24) was achieved by 96% of patients in the high dose lirentelimab group (n=80) compared to 5% in the placebo group (n=88)[24] - The high dose lirentelimab group (n=82) showed an absolute change in Dysphagia Symptom Questionnaire (DSQ) score of -174 compared to -119 in the placebo group (n=89)[27] - In adolescents (age 12-17), 100% of patients in both the high dose (n=16) and low dose (n=16) lirentelimab groups achieved histologic response compared to 6% in the placebo group (n=16)[43] - In adolescents, the high dose lirentelimab group (n=15) showed a -67% mean change from baseline in DSQ compared to -04% in the placebo group (n=16)[46] Clinical Study Results - ENIGMA2 (EG/EoD) - In the ENIGMA2 Phase 3 EG/EoD study, 85% of patients in the lirentelimab group (n=91) achieved histologic response compared to 4% in the placebo group (n=89)[62] - Patients receiving lirentelimab experienced a 98% mean reduction of eosinophils compared to a 24% reduction in the placebo group[64] - The lirentelimab group (n=75) showed an absolute change in Total Symptom Score (TSS6) of -115 compared to -100 in the placebo group (n=75)[66] - In ENIGMA1 site patients, the lirentelimab group (n=38) showed a mean TSS6 change from baseline of -142 compared to -80 in the placebo group (n=34)[74] Pipeline and Financials - Allakos completed a 35% reduction in workforce[190] - Allakos negotiated settlements to exit manufacturing and employee severance arrangements totaling approximately $150 million[190] - Allakos reported a cash balance of $424 million as of December 31, 2021[190]